Real-World Consensus on Treating HR+/HER2- Metastatic Breast Cancer

Rugo HS, Bardia A, Gradishar WJ, et al.

The REal-world TReatment patterns And Considerations of Toxicity in HR+/HER2-mBC (RETRACT) survey was designed to evaluate real-world practice patterns in disease testing and management. Based on responses from 150 US oncologists, most practice in accordance with guidelines; however, there were exceptions for substantial minorities related to the definition and treatment of visceral crisis, treatment for patients with endocrine resistance, routine use of next-generation sequencing for biomarker testing, and prophylactic measures for treatment-related adverse events in patients receiving alpelisib.